Pasireotide: 5 agencies, 2012–2018
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Assessment has run over 5.4 years, from 8 Oct 2012 at SMC (Scotland) to 21 Mar 2018 at HAS (France).
AWMSG (Wales) changed its position: recommended on 15 Jun 2016, not recommended by 12 Dec 2017.
No assessment is on file from PHARMAC (New Zealand), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for pasireotide, 2 submissions were never made — an outcome set by the company rather than the assessor.
Nothing has been added since 2018; on this evidence the file is dormant.
4 distinct indication wordings are recorded for pasireotide by the agencies that label one in English (AWMSG, PBAC and SMC).
1 of these 10 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess pasireotide, on 8 Oct 2012; AWMSG (Wales) did not open a file until 15 Jun 2016 — a wide spread of 3.7 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 4 of 10 dated records fall in 2015 alone.
3 of the 5 agencies here assessed pasireotide more than once, HAS (France) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed pasireotide.
The full ledger for pasireotide reads 4 recommended, 3 other, 2 non-submission and 1 not recommended.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 21 Mar 2018 | Listing (Transparency Committee) | ASMR V | source |
| SMC (Scotland) | 12 Feb 2018 | Treatment of adult patients with Cushing's disease for whom surgery is not an option or for whom surgery has failed. | not recommended | source |
| AWMSG (Wales) | 12 Dec 2017 | For the treatment of adult patients with Cushing’s disease for whom surgery is not an option or for whom surgery has fai… | not endorsed (non-submission) | source |
| TLV (Sweden) | 24 Nov 2015 | Signifor ingår i högkostnadsskyddet | general subsidy | source |
| PBAC (Australia) | 2015 | Inadequately controlled acromegaly | The PBAC recommended the listing of pasireotide as second-line therapy for the treatment o… | source |
5 further decisions for pasireotide, across 3 agencies, are not shown here. They link to 4 further source documents.
Related molecules
- lanreotide — same ATC class H01C — Pituitary and hypothalamic hormones
- octreotide — same ATC class H01C — Pituitary and hypothalamic hormones
- adrenaline — also decided by HAS in 2018Q1
- paroxetine — also decided by HAS in 2018Q1
- epoetin alfa — also decided by HAS in 2018Q1
- glibenclamide — also decided by HAS in 2018Q1
Coverage: 10 decisions for pasireotide from 5 agencies, 2012 to 2018. Data to 7 Sep 2026. ATC class H01C — Pituitary and hypothalamic hormones. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.